These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23843632

  • 21. Clinical pharmacokinetics of tyrosine kinase inhibitors.
    van Erp NP, Gelderblom H, Guchelaar HJ.
    Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
    [Abstract] [Full Text] [Related]

  • 22. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.
    Cancer Lett; 2009 Jun 28; 279(1):74-83. PubMed ID: 19232821
    [Abstract] [Full Text] [Related]

  • 23. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Wang J, Gan C, Sparidans RW, Wagenaar E, van Hoppe S, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Mar 28; 129():414-423. PubMed ID: 29155017
    [Abstract] [Full Text] [Related]

  • 24. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.
    Nucl Med Biol; 2015 Nov 28; 42(11):833-41. PubMed ID: 26264927
    [Abstract] [Full Text] [Related]

  • 25. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2017 Oct 02; 14(10):3258-3268. PubMed ID: 28880088
    [Abstract] [Full Text] [Related]

  • 26. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
    Tang SC, Sparidans RW, Cheung KL, Fukami T, Durmus S, Wagenaar E, Yokoi T, van Vlijmen BJ, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2014 Jun 15; 20(12):3133-45. PubMed ID: 24727322
    [Abstract] [Full Text] [Related]

  • 27. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

  • 28. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.
    J Pharmacol Exp Ther; 2010 Jun 29; 333(3):788-96. PubMed ID: 20304939
    [Abstract] [Full Text] [Related]

  • 29. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W, Sparidans RW, Wang Y, Lebre MC, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2018 Oct 15; 143(8):2029-2038. PubMed ID: 29744867
    [Abstract] [Full Text] [Related]

  • 30. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.
    Drug Metab Dispos; 2010 Aug 15; 38(8):1371-80. PubMed ID: 20423956
    [Abstract] [Full Text] [Related]

  • 31. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O.
    Clin Cancer Res; 2013 Apr 15; 19(8):2084-95. PubMed ID: 23461902
    [Abstract] [Full Text] [Related]

  • 32. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
    Ding JF, Zhong DF.
    Yao Xue Xue Bao; 2013 Jul 15; 48(7):1080-90. PubMed ID: 24133973
    [Abstract] [Full Text] [Related]

  • 33. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jan 15; 32(1):37-46. PubMed ID: 24962512
    [Abstract] [Full Text] [Related]

  • 34. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B.
    Drug Metab Dispos; 2009 May 15; 37(5):946-55. PubMed ID: 19225039
    [Abstract] [Full Text] [Related]

  • 35. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.
    Liao MZ, Gao C, Shireman LM, Phillips B, Risler LJ, Neradugomma NK, Choudhari P, Prasad B, Shen DD, Mao Q.
    Pharmacol Res; 2017 May 15; 119():61-71. PubMed ID: 28111265
    [Abstract] [Full Text] [Related]

  • 36. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL.
    Clin Cancer Res; 2008 Jun 15; 14(12):3881-8. PubMed ID: 18559609
    [Abstract] [Full Text] [Related]

  • 37. The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.
    Loos NHC, Sparidans RW, Heydari P, Bui V, Lebre MC, Beijnen JH, Schinkel AH.
    Toxicol Appl Pharmacol; 2024 Apr 15; 485():116911. PubMed ID: 38527694
    [Abstract] [Full Text] [Related]

  • 38. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S, Robey RW, Bates SE, Ambudkar SV.
    Drug Metab Dispos; 2009 Feb 15; 37(2):359-65. PubMed ID: 18971320
    [Abstract] [Full Text] [Related]

  • 39. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K.
    Eur J Pharmacol; 2015 Jan 05; 746():258-66. PubMed ID: 25455500
    [Abstract] [Full Text] [Related]

  • 40. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
    Wang J, Bruin MAC, Gan C, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Pharm; 2020 May 15; 581():119277. PubMed ID: 32234426
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.